TCMD stock rises on durable revenue growth and margin gains

Tactile Medical (ISIN US87874P1012) stock rises on a business update that still points to growth momentum in the latest reported year, with 2025 revenue at $309.7 million, up 19.0% from 2024. The company also reported 2025 adjusted EBITDA of $28.4 million and gross margin of 73.7%, while net income reached $6.8 million.

Revenue up 19.0%

The most useful signal for investors is the pace of top-line growth. Tactile Medical posted $309.7 million in revenue for 2025, compared with $260.9 million in 2024, which is a gain of $48.8 million year over year.

That change matters because it came with margin improvement rather than simple scale alone. Gross margin widened to 73.7% in 2025, while adjusted EBITDA reached $28.4 million, showing that the company converted a larger share of sales into operating profit.

Margin now matters

The same annual figures show a more disciplined earnings profile than in the prior year. Net income was $6.8 million in 2025, versus a loss of $0.2 million in 2024, a swing of $7.0 million year over year.

That combination - revenue up 19.0%, gross margin at 73.7%, and adjusted EBITDA at $28.4 million - gives the market a cleaner read on execution than a pure growth story would. For a medical device company, that mix usually carries more weight than sales alone.

Therapy sales drive volume

The company's business remains centered on home-based treatment systems for chronic edema and lymphedema, the categories that support repeat use and customer retention. Those therapies underpin the reported 2025 revenue base of $309.7 million.

Within that model, the annual report suggests that operating leverage is starting to show through. A $48.8 million increase in sales and a $28.4 million adjusted EBITDA result indicate that incremental revenue is increasingly being absorbed by a more efficient cost structure.

2025 revenue base

For Tactile Medical, the current valuation debate is likely to revolve around whether 19.0% annual revenue growth can be sustained without margin slippage. The 2025 gross margin of 73.7% suggests the company entered the new year with a healthy cushion.

The net income move from a $0.2 million loss in 2024 to $6.8 million in 2025 also gives the latest annual results a clearer earnings inflection point. That is the kind of shift that can matter more than a short-term headline move.

Home therapy remains central

The company's Flexitouch and related at-home compression systems remain the core commercial products behind the revenue profile. Those devices sit at the center of the 2025 sales figure of $309.7 million and the 73.7% gross margin base.

The product mix matters because it links recurring clinical need to a relatively high-margin reimbursement business. In 2025, that combination translated into $28.4 million of adjusted EBITDA and a return to positive net income.

Shares around the latest close

TCMD stock was not accompanied here by a fresh venue quote, so the most recent evidenced market context in this article is the companys 2025 report itself. Investors are left to weigh $309.7 million in annual revenue, $28.4 million in adjusted EBITDA, and $6.8 million in net income against the prior year figures.

The stock story is therefore anchored in the 2025 numbers: revenue up 19.0%, gross margin at 73.7%, and earnings moving back into positive territory. That is the clearest data point set available for the shares in this article.